Revolution Medicines sets final merger exchange ratio at 0.1112; ISS/Glass Lewis back deal

Revolution Medicines, Inc.

Final exchange ratio: 0.1112 RVMD shares per EQRx share, up from illustrative 0.0734.
ISS and Glass Lewis recommend RVMD stockholders vote FOR the share issuance.
Merger expected to add ~$1.1B net cash (~$20 per share issued); close targeted Nov 2023.
RVMD to issue ~55M shares (excl. warrants/earn-outs) for the acquisition.
RVMD special meeting of stockholders scheduled for November 8, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.